Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 1/20 | 0.40 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21561683 | 0.84 | CD38 (0.39) | CD38MAPK7FGFR4CDK5CDK5R1 | |
| SCHEMBL20191038 | 0.83 | CD38 (0.38) | CD38MAPK7FGFR4CDK5CDK5R1 | |
| SCHEMBL28851081 | 0.78 | L3MBTL1 (0.48) | CD38MAPK7FGFR4ACSS2HDAC1 | |
| SCHEMBL21561703 | 0.78 | ALDH1A1 (0.38) | CD38MAPK7FGFR4CDK5CDK5R1 | |
| Iodoacetamide SCHEMBL21543916 | 0.78 | CD38 (0.35) | CD38MAPK7FGFR4CDK5CDK5R1 | |
| SCHEMBL24801406 | 0.74 | CCNE1 (0.42) | CD38MAPK7FGFR4CDK5 | |
| SCHEMBL21941873 | 0.74 | L3MBTL1 (0.42) | CD38MAPK7FGFR4ACSS2 | |
| SCHEMBL20205010 | 0.73 | FGFR4 (0.35) | CD38MAPK7FGFR4CDK5CDK5R1 | |
| SCHEMBL20205014 | 0.72 | FGFR4 (0.40) | CD38MAPK7FGFR4ACSS2HDAC1 | |
| SCHEMBL21743433 | 0.71 | MAPK7 (0.35) | CD38MAPK7FGFR4ACSS2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | CD38 1747/4885MAPK7 2780/4885FGFR4 4027/4885 |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | CD38 1747/4885MAPK7 2780/4885FGFR4 4027/4885 |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | CD38 1747/4885MAPK7 2780/4885FGFR4 4027/4885 |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | CD38 1747/4885MAPK7 2780/4885FGFR4 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.